Date: 12/May / 2022
Your Name: Ton Hannolca.
Manuscript Title: Reliability of dynamic perfusion digital radiography as an alternative to pulmonary perfusion
scintigraphy in predicting postoperative lung function and complications
Manuscript number (if known): <u>JTD-22-383</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>✓</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None				
	lectures, presentations, speakers bureaus, manuscript writing or educational events					
6	Payment for expert	<u>✓</u> None				
	testimony					
7	Support for attending meetings and/or travel	<u>✓</u> None				
8	Patents planned, issued or	✓ None				
	pending					
9	Participation on a Data	✓ None				
	Safety Monitoring Board or	<u>- rone</u>				
	Advisory Board					
10	Leadership or fiduciary role in other board, society,	✓_ None				
•	committee or advocacy group, paid or unpaid					
11	Stock or stock options	✓_ None				
12	Receipt of equipment,	✓ None				
	materials, drugs, medical					
	writing, gifts or other services					
13	Other financial or non-	<u>✓</u> None				
	financial interests		· .			
Ĺ				•		
Ple	Please summarize the above conflict of interest in the following box:					
	The author declares no conflicts of interest associated with this manuscript.					
i						
İ						
L						
Ple	Please place an "X" next to the following statement to indicate your agreement:					

x I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: (2/May/2022
Your Name: Rysynke Kaka
Manuscript Title: Reliability of dynamic perfusion digital radiography as an alternative to pulmonary perfusion
scintigraphy in predicting postoperative lung function and complications
Manuscript number (if known): JTD-22-383

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	✓ None	
3	Royalties or licenses	✓_ None	
4	Consulting fees	✓ None	

5	Payment or honoraria for lectures, presentations,	<u>✓</u> None			
-	speakers bureaus, manuscript writing or		· .		
	educational events	<u> </u>			
6	Payment for expert testimony	<u>✓ None</u>	· · · · · · · · · · · · · · · · · · ·		
	testimony				
7	Support for attending meetings and/or travel	<u>✓</u> None			
			· · · · · · · · · · · · · · · · · · ·		
8	Patents planned, issued or	<u>✓</u> None			
	pending				
9	Participation on a Data	✓_None			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	✓ None			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	✓ None			
40					
12	Receipt of equipment, materials, drugs, medical	<u>✓</u> None			
	writing, gifts or other services				
13	Other financial or non-	<u>✓</u> None			
	financial interests				
_	Please summarize the above conflict of interest in the following box: The author declares no conflicts of interest associated with this manuscript.				
	ine author declares no con	nicts of interest associated	with this manuscript.		

Please place an "X" next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	12th	May	2022				
Your Name:	· P	KINAG	A SONUV	4			
Manuscript 1	Manuscript Title: Reliability of dynamic perfusion digital radiography as an alternative to pulmonary perfusion						
scintigraphy in predicting postoperative lung function and complications							
Manuscript number (if known): <u>JTD-22-383</u>							

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1`	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None				
	lectures, presentations, speakers bureaus, manuscript writing or					
	educational events					
6	Payment for expert	<u>✓</u> None				
	testimony					
7	Support for attending meetings and/or travel	✓ None				
	·					
8	Patents planned, issued or	<u>✓ None</u>				
	pending					
9	Dauticination on a Data	/ None				
9	Participation on a Data Safety Monitoring Board or	None				
	Advisory Board					
10	Leadership or fiduciary role	✓ None				
	in other board, society,					
	committee or advocacy group, paid or unpaid					
11	Stock or stock options	✓ None				
12	Receipt of equipment,	✓ None				
	materials, drugs, medical					
	writing, gifts or other services					
13	Other financial or non-	✓ None				
	financial interests					
Ple	Please summarize the above conflict of interest in the following box:					
	The author declares no conflicts of interest associated with this manuscript.					
			1			
L						
Ple	Please place an "X" next to the following statement to indicate your agreement:					

<u>x</u> I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 13. May, 2022
Your Name: Yo sullike Ohshio
Manuscript Title: Reliability of dynamic perfusion digital radiography as an alternative to pulmonary perfusion
scintigraphy in predicting postoperative lung function and complications
Manuscript number (if known): JTD-22-383

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>✓</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
-3	Royalties or licenses	✓_ None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	<u>✓</u> None	•	<u> </u>		
			. '			
	manuscript writing or					
<u> </u>	educational events			· · · · · · · · · · · · · · · · · · ·		
6	Payment for expert	✓ None				
	testimony					
7	Support for attending	✓ None				
	meetings and/or travel	<u> </u>				
8	Patents planned, issued or	✓ None				
	pending					
9	Participation on a Data	✓ None				
	Safety Monitoring Board or	<u>▼ None</u>	· · · · · · · · · · · · · · · · · · ·			
	Advisory Board					
10	Leadership or fiduciary role	✓ None				
	in other board, society,					
	committee or advocacy					
11	group, paid or unpaid Stock or stock options	✓_ None				
	Stock of Stock options	None -				
12	Receipt of equipment,	<u>✓</u> None				
	materials, drugs, medical					
	writing, gifts or other services					
13	Other financial or non-	✓ None				
	financial interests					
-		flist of interest in the fo				
PIE	Please summarize the above conflict of interest in the following box:					
	The author declares no conflicts of interest associated with this manuscript.					
- 1						

Please place an "X" next to the following statement to indicate your agreement:

<u>x</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: (3. May, 2032.					
Your Name: Keigo Chanata.					
Manuscript Title: Reliability of dynamic perfusion digital radiography as an alternative to pulmonary perfusion					
scintigraphy in predicting postoperative lung function and complications					
Manuscript number (if known): JTD-22-383					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	✓_ None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None			
	lectures, presentations,				
	speakers bureaus,	•			
	manuscript writing or				
<u> </u>	educational events	/ Name			
6	Payment for expert testimony	<u>✓</u> None			
	testimony				
7	Support for attending	✓ None			
′	meetings and/or travel	V None			
	meenings amay or travel				
8	Patents planned, issued or	✓ None			
	pending	V None	·		
	pending				
9	Participation on a Data	✓ None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	✓ None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	✓ None			
12	Receipt of equipment,	<u>✓ None</u>			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	✓ None			
	financial interests	<u>V</u> None			
	•				
	·	<u> </u>			
Ple	Please summarize the above conflict of interest in the following box:				
_					
	The author declares no conflicts of interest associated with this manuscript.				
L					
Ple	Please place an "X" next to the following statement to indicate your agreement:				

x I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:	13. Ma	y 202 ²
Your Name:	Takaya	Niratori
Manuscript Titl	le: <u>Reliability</u>	of dynamic perfusion digital radiography as an alternative to pulmonary perfusion
scintigraphy in	predicting po	ostoperative lung function and complications
Manuscript nu	mber (if knov	vn): JTD-22-383

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>✓</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	✓ None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	✓ None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	✓ None	
	testimony	None	
	,		
7	Support for attending	✓ None	,
	meetings and/or travel	<u> </u>	
	· ·		
8	Patents planned, issued or	✓ None	·
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or	and the second s	
	Advisory Board		·
10	Leadership or fiduciary role	✓ None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	/ Nana	
11	Stock or stock options	<u>✓ None</u>	
12	Receipt of equipment,	✓ None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services	:	
13	Other financial or non-	✓ None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fol	llowing box:
	The author declares no conf	licts of interest associated v	with this manuscript.
			`
L			

Please place an "X" next to the following statement to indicate your agreement:

<u>x</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: (3, May, 2022				
Your Name: Yo Kawaguchi				
Manuscript Title: Reliability of dynamic perfusion digital radiography as an alternative to pulmonary perfusion				
scintigraphy in predicting postoperative lung function and complications				
Manuscript number (if known): JTD-22-383				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	✓ None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None		
	lectures, presentations, speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	✓ None		
	testimony		· · · · · · · · · · · · · · · · · · ·	
7	Support for attending meetings and/or travel	<u>✓</u> None		
8	Patents planned, issued or	<u>✓</u> None		
	pending			
	Doubleinables en a Déta	/ Nece	· · · · · · · · · · · · · · · · · · ·	
9	Participation on a Data Safety Monitoring Board or	<u>✓</u> None		
	Advisory Board			
10	Leadership or fiduciary role	✓ None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	✓ None		
	Stock of Stock options	None		
		1 2		
12	Receipt of equipment,	✓ None		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	✓ None		
	financial interests	,		
_	Please summarize the above conflict of interest in the following box: The author declares no conflicts of interest associated with this manuscript.			
L pi₄	Please place an "X" next to the following statement to indicate your agreement:			

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.